Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-PRF and Botox for TMJ Anterior Disc Displacement
NCT06207955Completed
- Sponsor
- Fayoum University
- Start
- Jan 2024
- Primary completion
- Apr 2025
- Modality
- Recombinant Proteins and Enzymes, Device-based Delivery
- Countries
- 1
01
Overview
Trial of botulinum toxin type A and platelet rich fibrin in Anterior disc displacement with reduction (ADDwR) (3 arms), sponsored by Fayoum University. Primary endpoint: Maximum Mouth Opening at 6 months. Started Jan 2024; status: completed.
02
Drugs
botulinum toxin type Aplatelet rich fibrin
03
Conditions
Anterior disc displacement with reduction (ADDwR)
Beyond the preview
Go deeper on NCT06207955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207955.